| Biomarker ID | 106 |
| PMID | 16322291 |
| Year | 2005 |
| Biomarker | Methylation status of Cyclin D2 + APC |
| Biomarker Basis | Methylation Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in Patients who relapsed |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 4.33 (95% CI: 1.52 - 12.33) |
| Effect on Pathways | Pathways include (APC): Pathways in cancer, Signal transduction, Irinotecan pathway, Actin cytoskeleton regulation, Apoptosis |
| Experiment | Time to Progression |
| Type of Biomarker | Prognostic |
| Cohort | 74 patients who underwent radical prostatectomy for localised Prostate Cancer were chosen for the study. Over a period of 9 years 37 patients relapsed or died from recurrance. All the patients had a Gleason score of 7. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | 0.01 |
| Method Used | quantitative methylation specific PCR (QMSP) |
| Clinical | No |
| Remarks | HR for Multivariate Analysis (Considering Age, GSTP1, Cyclin D2 and APC). The major statistical end point of this study was time to progression (TTP). Progression included PSA elevations of >0.2 ng/mL, metastasis, and or death |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CCND2, APC |